Lexicon Pharmaceuticals, Inc. (LXRX)
NASDAQ: LXRX · Real-Time Price · USD
1.550
+0.140 (9.93%)
At close: Oct 6, 2025, 4:00 PM EDT
1.540
-0.010 (-0.65%)
After-hours: Oct 6, 2025, 5:01 PM EDT
Lexicon Pharmaceuticals Revenue
Lexicon Pharmaceuticals had revenue of $28.87M in the quarter ending June 30, 2025, with 1,652.64% growth. This brings the company's revenue in the last twelve months to $58.43M, up 1,504.83% year-over-year. In the year 2024, Lexicon Pharmaceuticals had annual revenue of $31.08M with 2,481.48% growth.
Revenue (ttm)
$58.43M
Revenue Growth
+1,504.83%
P/S Ratio
8.74
Revenue / Employee
$567,301
Employees
103
Market Cap
563.27M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 31.08M | 29.88M | 2,481.48% |
| Dec 31, 2023 | 1.20M | 1.07M | 766.19% |
| Dec 31, 2022 | 139.00K | -159.00K | -53.36% |
| Dec 31, 2021 | 298.00K | -23.70M | -98.76% |
| Dec 31, 2020 | 24.00M | -298.08M | -92.55% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
LXRX News
- 14 days ago - Lexicon Pharmaceuticals Announces Update on Submission of Additional Data to U.S. FDA Supporting the Benefit-Risk Profile of Zynquista® in Type 1 Diabetes - GlobeNewsWire
- 19 days ago - Pilavapadin Provides Meaningful Pain Reduction in Adults with Diabetic Peripheral Neuropathic Pain (DPNP) in Data Presented at the European Association for the Study of Diabetes (EASD) and NEUROdiab Annual Meetings - GlobeNewsWire
- 25 days ago - Lexicon Pharmaceuticals to Present Additional Clinical Data on Pilavapadin at Three Upcoming Medical Meetings - GlobeNewsWire
- 4 weeks ago - Lexicon Pharmaceuticals Announces Submission of Additional Data to U.S. FDA Supporting the Benefit-Risk Profile of Zynquista® in Type 1 Diabetes - GlobeNewsWire
- 4 weeks ago - Lexicon Pharmaceuticals to Present New Preclinical Data on Pilavapadin in Chemotherapy-Induced Pain and Multiple Sclerosis Pain at NeuPSIG 2025 - GlobeNewsWire
- 4 weeks ago - Lexicon Pharmaceuticals, Inc. (LXRX) Presents At Citi's Biopharma Back To School Conference Transcript - Seeking Alpha
- 4 weeks ago - Lexicon Pharmaceuticals Announces Presentation of Diabetic Peripheral Neuropathic Pain Patient Insights at PAINWeek 2025 - GlobeNewsWire
- 4 weeks ago - Sotagliflozin Provides Consistent Relative Risk Reduction in Heart Failure and Major Cardiovascular Events Across All Age Ranges, Including Greater Than 75, in Data Presented at the European Society of Cardiology (ESC) 2025 Congress - GlobeNewsWire